Lone atrial fibrillation in elderly persons: a marker for cardiovascular risk.

BACKGROUND The risk of stroke in persons aged 60 years and younger with lone atrial fibrillation (LAF) is no greater than in the general population. The effect of older age on the risk of stroke in persons with LAF is less well established. PARTICIPANTS AND METHODS The risk of stroke in persons with LAF and without substantial comorbidities was examined in a population-based study at a single institution in Olmsted County, Minnesota, and compared with that in an age- and sex-matched population. The mean age was 74 years (range, 61-97 years). The median duration of follow-up was 9.6 years until death or last follow-up. RESULTS Of 55 patients, 26 had 31 cardiovascular events during follow-up, occurring a median of 5.1 years after diagnosis (range, 0.7-18 years). Of 11 cerebrovascular events, 6 were transient ischemic attacks and 5 were strokes. The event rates (percentage per person-year) were 0.9% for stroke, 1.1% for transient cerebral ischemia, and 2.6% for myocardial infarction, for a total cardiovascular event rate of 5.0% per person-year. The corresponding rates for the age- and sex-matched control group were 0.2%, 0%, and 1.1%, for a total of 1.3% per person-year. The incidence of total cardiovascular events was significantly greater (P< .01) in those with LAF, although there was no difference in survival. CONCLUSION Lone atrial fibrillation occurring after age 60 years is a risk marker for a substantial increase in cardiovascular events that warrants consideration for antithrombotic therapy.

[1]  D. Petitti,et al.  Duration of warfarin anticoagulant therapy and the probabilities of recurrent thromboembolism and hemorrhage. , 1986, The American journal of medicine.

[2]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.

[3]  P. Wolf,et al.  Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study. , 1985, JAMA.

[4]  W. O'Fallon,et al.  Prospective comparison of a cohort with asymptomatic carotid bruit and a population-based cohort without carotid bruit. , 1990, Stroke.

[5]  Predictors of Thromboembolism in Atrial Fibrillation: II. Echocardiographic Features of Patients at Risk , 1992, Annals of Internal Medicine.

[6]  P. Wolf,et al.  Epidemiologic assessment of chronic atrial fibrillation and risk of stroke , 1978, Neurology.

[7]  R. W. Achor,et al.  Problems Associated with Long‐Term Anticoagulant Therapy: Observations in 139 Cases , 1962, Circulation.

[8]  Palle Petersen,et al.  PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION The Copenhagen AFASAK Study , 1989, The Lancet.

[9]  P. Wolf,et al.  Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. , 1987, Archives of internal medicine.

[10]  W. Hauser,et al.  Complications of long‐term anticoagulation , 1988, Annals of neurology.

[11]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[12]  D L McGee,et al.  Duration of atrial fibrillation and imminence of stroke: the Framingham study. , 1983, Stroke.

[13]  B. Gersh,et al.  The natural history of lone atrial fibrillation. A population-based study over three decades. , 1987, The New England journal of medicine.

[14]  Denis Roy,et al.  Usefulness of anticoagulant therapy in the prevention of embolic complications of atrial fibrillation. , 1986, American heart journal.

[15]  J. Forfar.  A 7-year analysis of haemorrhage in patients on long-term anticoagulant treatment. , 1979, British heart journal.

[16]  S. Husted,et al.  Problems encountered in long-term treatment with anticoagulants. , 2009, Acta medica Scandinavica.

[17]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[18]  A. Belanger,et al.  The Framingham study. , 1976, British medical journal.

[19]  W. Kannel,et al.  Epidemiologic features of chronic atrial fibrillation: the Framingham study. , 1982, The New England journal of medicine.

[20]  J. Roos,et al.  The cause of bleeding during anticoagulant treatment. , 2009, Acta medica Scandinavica.

[21]  T. Moreland,et al.  Age as a determinant of sensitivity to warfarin. , 1977, British journal of clinical pharmacology.

[22]  V. Fuster,et al.  Antithrombotic therapy in cardiac disease. An emerging approach based on pathogenesis and risk. , 1989, Circulation.

[23]  L. Ivan,et al.  Neurosurgical complications of anticoagulant therapy. , 1973, Canadian Medical Association journal.

[24]  J. Crooks,et al.  Determinants of anticoagulant control in patients receiving warfarin. , 1977, British journal of clinical pharmacology.

[25]  J. Gurwitz,et al.  Age-related risks of long-term oral anticoagulant therapy. , 1988, Archives of internal medicine.

[26]  H. White,et al.  Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation : stroke prevention in atrial fibrillation II study. Commentary , 1994 .

[27]  Predictors of Thromboembolism in Atrial Fibrillation: I. Clinical Features of Patients at Risk , 1992, Annals of Internal Medicine.

[28]  RISKS OF LONG-TERM ORAL ANTICOAGULANT THERAPY IN ELDERLY PATIENTS AFTER MYOCARDIAL INFARCTION Second Report of the Sixty Plus Reinfarction Study Research Group , 1982, The Lancet.

[29]  Leandro Provinciali,et al.  Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke , 1993 .

[30]  M. Peyman.  The significance of haemorrhage during the treatment of patients with the coumarin anticoagulants. , 2009, Acta medica Scandinavica. Supplementum.

[31]  F. Davis,et al.  Management of anticoagulation in outpatients: experience with an anticoagulation service in a municipal hospital setting. , 1977, Archives of internal medicine.

[32]  E. Kokmen,et al.  Trends in incidence of dementing illness in Rochester, Minnesota, in three quinquennial periods, 1960–1974 , 1988, Neurology.

[33]  Bernard Rosner,et al.  The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. , 1990, The New England journal of medicine.

[34]  Lippincott Williams Wilkins,et al.  Stroke Prevention in Atrial Fibrillation Study: Final Results , 1991, Circulation.

[35]  P. W. Willis,et al.  Hemorrhagic complications of anticoagulant therapy. , 1974, Archives of internal medicine.